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Portacaval shunt was performed in ten patients with homo-
zygous and two with heterozygous familial hypercholester-
olemia (FH). Total serum cholesterol was lowered by 20% to 
55.4% during follow-up periods of 14 months to almost 9 years, 
with commensurate decreases in LDL cholesterol. The effect 
on HDL cholesterol and triglyceride levels was variable. Ten-
dinocutaneous xanthomas diminished or disappeared. Growth 
and development in children proceeded or accelerated. There 
was no detectable emotional or intellectual deterioration. He-
patic failure did not occur, although blood ammonia concen-
trations and serum alkaline phosphatase levels increased rel-
ative to preoperative values. Cardiac symptoms were often im-
proved, but evidence of reversal of cardiovascular lesions was 
inconclusive. Three patients with pre-existing heart disease 
died of cardiac complications after 4 months, 18lfz months, and 
30 months. Portacaval shunt has been effective therapy for 
patients with FH who were refractory or intolerant to medical 
treatment; it should be performed before the development of 
irreversible cardiovascular damage. 
I N MARCH 1973, a 12-year-old girl with homozygous familial hypercholesterolemia (FH) was treated with 
end-to-side portacaval shunt. Her serum cholesterol and 
low density lipoprotein concentrations were lowered sig-
nificantly.' This same effect of portal diversion has been 
seen by us in other cases2 and has been confirmed else-
where. 3- 12 
Portal diversion has not been widely applied in pa-
tients with FH, partly because the long-term influence 
of the operation on the disease has not been known. In 
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addition, there has been anxiety about the potential risks 
of portacaval shunt, including the possibilities of hepatic 
encephalopathy and/or intellectual deterioration. To 
answer these questions of effectiveness and morbidity, 
we report here on the fate of 12 patients with FH who 
were treated with portacaval shunt from 14 months to 
10 years ago. 
Methods 
Information about the 12 patients is given in Table 
1. Eight of the patients were children. All of the patients 
had FH and all but two were homozygous for the ab-
normality. Low density lipoprotein (LDL) receptors 
were determined by Goldstein and Brown l3 ,14 on cul-
tured fibroblasts obtained from all patients (Table 1) and 
many of their close relatives. Nine of the ten patients 
with homozygous disease were LDL receptor-negative 
and the other was receptor-defective. One of the two 
patients (patient 11) with heterozygous disease was from 
a kindred in which FH homozygous relatives were re-
ceptor-negative. The other (patient 6) had no relatives. 
Continuity of care before and after portacaval shunt 
was at the referring university centers (Table 1) where 
special metabolic, vascular, and other studies were and 
are being performed. The clinical observations and bio-
chemical data were obtained at these centers. 
Except for the 2-year-old child, all of the patients had 
been treated for long periods before a conclusion was 
reached that they were refractory to or noncompliant 
with medical management. Previous treatment had al-
ways included a diet low in saturated fat and cholesterol 
as well as the lipid lowering medications listed in Table 
1. Plasmapheresis had been tried in five of the 12 pa-
tients and had been stopped because of inconvenience, 
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TABLE 1. Clinical Features of 12 Patients with Familial Hypercholesterolemia (FHJ 
LDL Receptor Portacaval 
Principal Care Center Age/Sex Status Previous Treatment Shunt Date 
l. (JP) University of Colorado, Denver 12/F Negative Diet, cho1estyramine, nicotinic acid, clofibrate, 3-1-73 
dextro-throxine 
2. (MC) Southwestern University, Dallas 7/F Negative Diet, cholestyramine, nicotinic acid, clofibrate 10-4-74 
3. (FV) Universite Rene Decarte, Paris 81M Negative Diet, cholestyramine, nicotinic acid, clofibrate, 8-5-75 
plasmapheresis 
4. (AM) Rockefeller University, New 5/M Negative Diet, cholestyramine, nicotinic acid, clofibrate 12-14-78 
York City 
5. (CP) National Institutes of Health, 141M Negative Diet, cholestyramine, nicotinic acid, clofibrate, 6-19-79 
Bethesda dextra-thyroxine, hydroxy-methyl glutaric 
acid, colestipol, plasmapheresis 
6. (PC) Rockefeller University, 52/M Heterozygote Diet, cholestyramine, nicotinic acid, clofibrate, 8-7-79 
New York City (50% of normal) colestipol, Beta-sitosterol 
7. (JC) University of Colorado, Denver IO/M Negative Diet, cholestyramine, nicotinic acid, colestipol, 11-10-79 
plasmapheresis 
8. (DP) University of Cincinnati, 31/F 20% of normal Diet, cholestyramine, nicotinic acid, dextro- 4-21-81 
Cincinnati thyroxine, plasmapheresis 
9. (TH) National Institutes of Health, 21/F Negative Diet, cholestyramine, or colestipol, nicotinic 11-11-81 
Bethesda acid, clofibrate, plasmapheresis 
10. (DP) National Institutes of Health, 7/M Negative Diet, cholestyramine, nicotinic acid, 
Bethesda neomycin, colestipol, d-thyroxine 
11.* (HP) National Institutes of Health, 371M Heterozygote Diet, cholestyramine, or colestipol, nicotinic 11-17-81 
Bethesda (50% of normal) acid, neomycin 
12. (MW) University of California, 2/F Negative 
Los Angeles 
* Father of patient 10, uncle of patient 5. 
poor acceptance by the patients, ineffectiveness, or all 
three reasons. After portacaval shunt, the majority of 
the patients were treated again with one or more of these 
measures. The conditions that pertained at blood sam-
pling times before and after operation are noted in 
Table 2. 
All 12 patients had tendinous and cutaneous xantho-
mas, These were prominent in eight of the ten patients 
who had homozygous disease. In each patient, the pres-
ence of cardiovascular disease was looked for with cath-
eterization and/or non-invasive techniques. The only 
patient who was free of cardiovascular disease was 2 
years old (Table 3). The most common diagnoses were 
aortic stenosis, coronary artery disease, and atheroscle-
rosis of the aorta or its large branches (Table 3). Five 
of the patients had sustained a previous myocardial in-
farction, and four had undergone a coronary artery by-
pass operation (Table 3). Four patients had angina pec-
toris and five more had a history of angina that had been 
relieved following a myocardial infarction or coronary 
artery bypass. 
To assure accuracy of preoperative and postoperative 
comparisons in individual cases, serum cholesterol levels 
Diet, cholestyramine, nicotinic acid 3-11-82 
were included for analysis only when these were mea-
sured at the same center. The analytic techniques were 
based on the Liebermann-Burchard color reaction15 or 
on enzymatic assay.16 In most cases, less frequent de-
terminations were made of serum triglycerides, low den-
sity lipoprotein (LDL) cholesterols, and high density li-
poprotein (HDL) cholesterols. Standard liver function 
tests were obtained. 
The portacaval shunts were performed by anasto-
mosing with fine continuous suture the cut end of the 
portal vein to an elliptical defect in the anterior or an-
terolateral wall of the suprarenal inferior vena cava. 
Tributaries to the portal vein above the site of its tran-
section were looked for and ligated. The anastomoses 
were made slightly larger than the natural diameter of 
the portal vein. Although hypercoagulability has been 
described in FH,17 no anticoagulants were given during 
or after operation. Thrombosis after portacaval shunt 
in children with portal hypertension has been so high 
that most pediatric surgeons prefer to use the operation 
only in patients older than 8 or 10 years and for those 
whose anastomosis can be made at least 1 cm in di-
ameter. 18,19 Although these minimum conditions did not 
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TABLE 3. Effect of Portacaval Shunt on Cardiovascular Disease and Visible Xanthomas 
Previous Cardiovascular Postop Cardiovascular Tendinocutaneous Other Clinical Months 
Case Status· Examination Xanthomas Observations (Postop) Follow-up 
1. Aortic stenosis, and Regression of aortic stenosis Disappeared Resumed normal 181h (died) 
insufficiency, multiple and coronary artery disease; activities except 
lesions of coronary marked improvement of competitive sports 
arteries, myocardial heart failure; died of 
infarction one month arrhythmia 
previously, ventricular 
aneurysm, heart failure 
2, Aortic stenosis, bulky ath- Double coronary artery bypass Disappeared Normal life, participates 103 
eromas thoracic aorta, plus aortic and mitral valve in sports such as soccer 
multiple lesions of cor- replacement, November, and basketball 
onary arteries 1976; Out-grown heart valves 
replaced, February 1981; now 
stable 
3. Aortic stenosis, large ath- Restudied June 1982. Aortic Almost gone, but tiny Nearly normal activities, 93 
eromas on angiogram valves atrophic and moder- satellite lesions re- including soccer and 
in ascending thoracic ately insufficient, ascending centiy developed jogging 
and abdominal aorta, aortic atheroma persistent near old xanthoma 
carotid and femoral with 36-mmHg gradient, sites. 
bruits, coronary arteries Right coronary artery nor-
patent mal, Left coronary artery not 
cannulated. Dilatation and 
hypertrophy left ventricle 
4. Mild aortic stenosis; nor- No change clinically Markedly diminished Normal activities 53 
mal coronary arteries, 
normal exercise stress 
test 
5. Aortic stenosis, atheroma Myocardial infarction 7 months Only skin stains re- Restricted activities, de- 30 (died) 
mass ascending aorta, postop, with ventricular aneu- mained veloped renal stones 
multiple lesions of cor- rysm and heart failure; died 
onary arteries, heart of heart failure and arrhyth-
failure, peripheral bruits mia 
6. Multiple lesions of coro- Same clinically Not prominent before, Minor activity restrictions, 45 
nary arteries, previous diminishing moderate improvement 
myocardial infarction, 
previous coronary ar-
tery bypass, left ventl1c-
ular dilatation 
7. Aortic stenosis and insuf- Aortic stenosis gradient reduced Disappeared Normal activities 42 
ficiency, atheromas on and aortic atheromas stable 
angiogram in aorta, on restudy after one year. 
coronary arteries patent Coronary arteries normal 
8. Aortic stenosis, multiple No change clinically Diminished Has severe but quiescent 29 
lesions of coronary ar- multiple sclerosis, gen-
teries, previous myocar- eral condition and ac-
dial infarction, previous tivity level improved 
coronary artery bypass 
9. Aortic stenosis, multiple Died 4 months heart failure, ar- Not prominent before, Not rehabilitated because 4 (died) 
lesions of coronary ar- rhythmia, diffuse coronary diminished of pre-existing heart 
teries previous myocar- disease at autopsy disease 
dial infarction, previous 
coronary artery bypass, 
heart failure 
10. Aortic stenosis, coronary No change clinically 
arteries open, ileofe-
Diminishing Slightly restricted 18 
moral bruits 
II. Multiple lesions of coro- Improved clinically Not prominent before, Slightly restricted activi- 18 
nary arteries, previous diminishing ties 
myocardial infarction, 
previous coronary ar-
tery bypass 
12. No abnormalities clini- No change clinically Diminishing Normal activities 14 
cally 
* Preoperative catheterization and angiography in all except patient angina already had been relieved in patients I, 6, 8, 9, and II by a 
12; postoperative repeat studies in patients 1,2,3,5, and 7. Patients myocardial infarction or coronary artery bypass. 
2, 3, 5, and 10 had angina pectoris immediately before operation, and 
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obtain in the majority of our patients, there were no 
technical difficulties. 
Results 
Convalescence following portacaval shunt was prompt 
and uncomplicated. Patients 1, 5, and 9 died of heart 
disease after 18 112 months, 30 months, and 4 months, 
respectively. The other nine patients are alive after 14 
to 103 months (Table 3). 
Effect Upon Serum Lipids 
Total serum cholesterol concentrations fell signifi-
cantly in every patient after portacaval shunt (Table 2). 
When measured, LDL cholesterol levels were reduced 
commensurately (Table 2). The total cholesterol level 
declines were 20% to 55.4% (average 33.8%) and were 
maintained throughout the period of study. The de-
creases were evident in 1 to 4 weeks and had reached 
a relatively stable new level by 2 or 3 months. 
In patient 4, two sets of results were available. As an 
outpatient on a low cholesterol diet, this child with ho-
mozygous disease had total serum cholesterol levels be-
fore operation of 745 ± 51 (SD) mg/dl. Afterwards, these 
fell to 533 ± 24 mg/dl. With these conditions, the total 
serum cholesterol reduction was 28.5%. During meta-
bolic studies in the hospital, he was given a liquid for-
mula diet containing 150 mg/day cholesterol with a 
polyunsaturated/saturated fat ratio of 0.4. Both the base-
line and post-shunt cholesterol levels were lower on this 
restrictive diet, with a reduction of 23.5% after opera-
tion. The in-hospital data is given in Table 2. 
Most of the patients were kept on the same medical 
management after operation as that used before. How-
ever, the cholesterol levels dropped by 38%, 20%, and 
39% in patients 3, 8, and 10, respectively, despite dis-
continuance of all medications and relaxation of diet. 
In patient 2, a previously reported immediate decline 
of 41 %20 was increased to 46% (Table 2) after other drugs 
were added to diet and cholestyramine. 
Because of a myocardial infarction 7 months after 
portacaval shunt, patient 5 was started on monthly plas-
mapheresis. Portal diversion had already caused a 34% 
reduction in serum cholesterol (Table 2). Before oper-
ation, plasmapheresis had been tried and eventually 
stopped because of the return of serum cholesterol to 
baseline levels within 10 days after each treatment. Now, 
plasmapheresis caused a greater reduction in serum cho-
lesterol which required 20 days for recovery. 
Serum triglyceride levels also usually fell, but this 
change was significant in only five of nine cases, in which 
sufficient data were available for assessment (Table 2). 
A significant rise was seen in patient 4. HDL cholesterol 
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FIG. 1. Percentile height position, taken from standard growth charts, 
of the first six pediatric patients before and after portacaval shunt. All 
patients gained height after operation more rapidly than before, caus-
ing their percentile position to move up on the age-corrected growth 
charts. 
values were available from eight patients; significant falls 
were seen in only two patients (Table 2). Significant 
increases in HDL cholesterol were not seen. 
All 12 patients with tendinocutaneous xanthomas had 
regression or disappearance of the lesions (Table 3). If 
the xanthomas were prominent, complete disappear-
ance, when this was achieved, required 1112 to 3 years. 
Physical and Emotional Development 
Four of the first six pediatric patients were below av-
erage in height development, and five patients had ex-
hibited a recent failure to grow. All six patients had 
growth spurts after operation (Fig. 1). Similar weight 
trends were seen (Fig. 2). 
None of the 12 patients had emotional or intellectual 
deterioration. Patients 4 and 6 had full verbal perfor-
mance assessment of their intelligence quotient (I.Q.) 
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age-corrected standard growth charts. All patients gained weight after, 
and all but patient 4 improved their percentile position. 
using the Stanford Binet or Wechsler tests before op-
eration and 1112 years later. Their scores did not change. 
Hepatic and Renal Function 
There were no major changes in bilirubin, prothrom-
bin time, and serum protein concentration. Several of 
the patients had minor fluctuations in serum trans-
aminase levels. Elevations in alkaline phosphatase were 
common but not progressive. 
Sporadic increases of blood ammonia levels were seen 
after operation in patients who had multiple tests. Usu-
ally, the elevations were at or just above the upper ref-
erence range for the laboratory being used. Four patients 
had studies before and after portacaval shunt at the 
National Institutes of Health laboratories, where the 
normal blood ammonia range is 19 to 60 JIg/dl. Before 
operation, blood ammonia concentrations in the four 
patients were 46.4 ± 7.6 (SD) JIg/dl, and after operation, 
these were 79.0 ± 22.9 JIg/dl (p < 0.05). In the other 
cases in which the first determinations were postoper-
ative, the highest postoperative values observed were in 
patient 6, a 52-year-old man with heterozygous disease 
who had ammonia concentrations as high as 200 JIg/dl. 
As a result, he was placed for 14 months on a low-protein 
diet. Then, he was returned uneventfully to a diet con-
taining 12% to 15% of calories as protein, with no in-
crease in blood ammonia levels. He never developed 
encephalopathy and he was one of the patients whose 
I.Q. did not change. 
Only one of the 12 patients has had clinical mani-
festations of hepatic encephalopathy. The exception was 
2-year-old patient 12, who had a single episode of un-
consciousness nine months after portacaval shunt at a 
time when the blood ammonia concentration was 85 
JIg/dl (normal in that laboratory was less than 55 JIg/dl). 
Encephalopathy was accepted as the diagnosis because 
no other explanation was found. The child was placed 
temporarily on a low-protein diet and has now resumed 
a normal diet. 
Renal function was not changed. Patient 5 developed 
renal stones one year after portacaval shunt. The stone 
formation was ascribed to hypercalcuria associated with 
the use of diuretics. However, the composition of the 
stones was not determined. Urologic care was not re-
quired. 
Cardiovascular Disease 
Patients 4, 10, and 12, who had no preoperative car-
diac complaints, have remained asymptomatic for 44 
months, 9 months, and 5 months after portacaval shunt, 
respectively, (Table 3). Eight of the other nine patients 
claimed improvement in physical activity and a reduc-
tion in symptoms which included angina pectoris in four 
of them. However, three of the nine patients died of 
cardiac complications at 4 months (patient 9), 18IJ2 
months (patient 1), and 30 months (patient 5); all of the 
portacaval shunts were widely patent at autopsy. All 
three patients had proven coronary artery disease before 
operation, and two had previously survived myocardial 
infarctions that had left them with chronic heart failure. 
The death of patient 1 was ascribed to an arryhthmia,21 
since reversal of coronary artery atherosclerosis was 
thOUght to be occurring on the basis of repeat coronary 
angiograms.22 The heart failure of patient 9 became in-
tractible after an attempt at post-shunt plasmapheresis, 
and she died of an arrhythmia several weeks later. Pa-
tient 5 had his first myocardial infarction 7 months after 
operation at a time when tendinocutaneous xanthomas 
were shrinking; despite efforts to expedite removal of 
lipid deposits by the addition of monthly plasmapher-
esis, he died of heart failure and an arrhythmia 2 years 
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later. At autopsy, the distal coronary arteries were in 
good condition. The proximal right coronary ostium was 
occluded partially, but the left coronary ostium was 
open. There was a partially occlusive atheromatous mass 
in the proximal ascending aorta. A similar mass with 
a present pressure gradient of 36 mmHg has been pres-
ent in patient 3 for 7 years. During this time, aortic 
stenosis may have regressed but with residual aortic in-
sufficiency. 
Two definite examples of reversal of aortic stenosis 
were documented by cardiac catheterization. A gradient 
reduction from 56 to 10 mmHg occurred in patient I 
in 16 months.22 A decline from 40 to 24-30 mmHg was 
seen in patient 7 over 13 months, during which time 
large atheromas of the thoracic aorta were unchanged. 
Coronary angiography before and from 7 months to 
7 years after portacaval shunt was performed in five 
cases (patients 1, 2, 3, 5, and 7) but was technically 
difficult because of the atheromatous disease of the aor-
tic valves and ascending aorta. The appearance of the 
coronary arteries was thought to be better in patient 1, 
uninterpretable in patient 3, unchanged in patients 2 
and 7, and possibly worse in patient 5. In patient 5, 
coronary angiography 9 months after portacaval shunt 
and 2 months after myocardial infarction did not show 
worsening of a 50% narrowing of the ostium of the right 
main coronary artery. It was suspected that spasm or an 
embolus to the left coronary artery may have been re-
sponsible for his large anterior wall myocardial infarc-
tion and ventricular aneurysm since the left main and 
left anterior descending coronary arteries were patent. 
Patient 2 had a double coronary artery bypass and 
replacement of the aortic and mitral valves 25 months 
after portacaval shunt. Her rapid growth rate (Fig. 1) 
necessitated replacement of both valves 41f2 years later. 
At reoperation, the coronary artery reconstructions were 
open, and the prosthetic valves were in good condition. 
Her rehabilitation has been complete. 
Discussion 
The effects of completely diverting portacaval shunt 
on liver structure are common to all species studied so 
far,23 including humans with FH.I These include he-
patocyte atrophy, glycogen depletion, fatty infiltration, 
and drastic alteration of the organelles. I ,23-27 The re-
duction of hepatocyte rough endoplasmic reticulum 
with depletion of its polyribosomes is unusually prom-
inent23- 25 and is the probable explanation for reductions 
in many biosynthetic processes. These alterations are 
explained by the fact that the liver is deprived of first-
pass exposure to hormones (especially insulin) and other 
putative hepatotrophic factors from splanchnic vis-
cera.24-27 
The hepatic changes caused by portacaval shunt are 
thought to be responsible for the hepatic encephalopa-
thy, inanition and hair loss that occur regularly in dogs, 
inconstantly in other species, and to an apparently in-
significant degree in humans with a previously undam-
aged liver. It has been known since the last century28 
that the complex physiologic and morphologic events 
following portacaval shunt do not occur or are mini-
mized by shunt thrombosis and stenosis or by revas-
cularization by splanchnic collaterals of the tied offpor-
tal vein above the site of anastomosis. In normal 
dogs,24,29 and baboons,24 partial diversion of the portal 
venous blood does not cause the lowering of serum cho-
lesterol levels that is seen after total portacaval shunt. 
After portacaval shunt, patients with Type I glycogen 
storage disease have striking reductions of serum choles-
terol, triglyceride, and phospholipid levels.3o This obser-
vation was an important factor in the decision to perform 
portal diversion in the first patients with FH.I The same 
cholesterol lowering effect was observed in all of our pa-
tients with homozygous or heterozygous FH. The LDL 
membrane receptor status was not predictive of the extent 
of the decline. Total serum cholesterol concentrations 
(and LDL cholesterol levels when measured) fell 20% to 
55.4% while the patients were on comparable, or fre-
quently less rigid, programs of medical management than 
those used after surgery. HDL cholesterol and triglyceride 
levels were variably effected. Tendinocutaneous xantho-
mas regressed or disappeared in every patient. 
The consistency of the anticholesterolemic response 
was greater than that noted by other authors who have 
reported on a total of 26 additional patients, 13 of whom 
were treated in Johannesburg. 12 In the 13 treated else-
where than Johannesburg,3,5-11 serum cholesterol re-
ductions of at least 30% were obtained in ten patients 
at the same time as tendinocutaneous xanthomas re-
gressed. In two of the three exceptional patients, shunt 
thrombosis was proved,5,6 and in one of these, the cho-
lesterollevel fell by 40% after a later mesocaval shunt. 31 
In the third patient, reported by Soutar, Myant, and 
Thompson,s there was presumptive evidence of shunt 
occlusion. An early cholesterol fall of 40% returned sev-
eral months later to nearly preoperative values. At the 
same time, initially elevated serum glucagon levels, 
which are typically found with a patent shunt,2o,32 fell 
to baseline. 
The eady4 and subsequentl2 reports from Johannes-
burg have confirmed the value of portacaval shunt in 
FH, but have provided minimal incentive for expanded 
trials. Of 13 homozygous patients with unstipulated 
membrane receptor status, one died 2 days after oper-
ation of a myocardial infarction. The remaining 12 pa-
tients had significant but often modest falls in serum 
total and LDL cholesterol levels, which later returned 
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to or toward preoperative levels in three patients. Xan-
thomas regressed in eight patients, were stable in two 
patients, and increased in two patients. Almost all of the 
patients developed postoperative splenomegaly, a find-
ing compatible with sluggish or obstructed splanchnic 
venous drainage or alternatively with a manifestation 
of FH that previously had not been appreciated. 12 
One of the Johannesburg patients was proved to have 
an occluded portacaval shunt (splenorenal shunt was 
performed later with a good result), another was dem-
onstrated to have revascularization of the portal vein 
stump with a large splanchnic collateral, and the rest 
were not studied with angiographic techniques, since 
they had not developed esophageal varices. However, 
sudden occlusion of the portal vein in subhuman pri-
mates and in humans often does not cause portal hy-
pertension and varicesY Physiologic evidence of shunt 
patency, such as that obtainable by demonstrating post-
prandial hyperglucagonemia2o,32 or hyper-bile acide-
mia2o,34 was not given. Forman et al. 12 speculated that 
the unevenness of the results could have been due to 
ineffective portal diversion in some cases, to peculiarities 
of the FH which is endemic in that region, or to other 
less obvious factors. 
The invariable and long-lasting lipid lowering in our 
12 patients was achieved with little surgical morbidity. 
There has been no suspicion that any of the shunts has 
dosed. The physical development of those children who 
were normal before has proceeded and the growth of 
those who were stunted before operation has moved to-
ward normal. Emotional or intellectual deterioration 
secondary to the portal diversion has not occurred, as 
was once feared following the report of Voorhees et al. 35 
Detailed I.Q. and psychologic examinations in two pa-
tients were unchanged before and after operation. There 
were no major perturbations of standard liver function 
tests, although increases of alkaline phosphatase were 
common. When measured, blood ammonia levels were 
always elevated, the most extreme example being in an 
asymptomatic adult who was treated for the first 14 post-
operative months with a low-protein diet. Such tem-
porary protein restriction also was prescribed for patient 
12. One year after operation, one of the patients devel-
oped renal stones of unknown composition. Uric acid 
stones can be caused in rats by portacaval shunt. 36 
The mechanisms by which portal diversion reduces 
serum lipids probably are qualitatively similar in normal 
experimental animals and in patients with FH. After 
portacaval shunt, reductions of more than 80% in he-
patic cholesterol and triglyceride synthesis were dem-
onstrated in dogs.24 Although a similar diminution in 
cholesterol and/or lipoprotein synthesis was confirmed 
in rats,37-39 dogs,40 swine,41-43 and baboons,4o not all 
workers could verify these findings.44- 47 The rigorously 
controlled studies in rats by Proia et aI.,38 which are the 
only rep0l1ed animal experiments in which body weights 
were maintained or increased after operation, have done 
much to explain the latter discordant reports. In addition 
to a reduction in cholesterol synthesis, Proia et a1.38 
made the crucial observation that the total body cho-
lesterol pool was diminished after portal diversion. 
Data relevant to mechanisms in humans with FH are 
also available. Soutar et al.8 found no change in LDL 
synthesis and an actual rise in VLDL synthesis in the 
patient discussed earlier whose shunt may have been 
closed. Strikingly different conclusions have been reached 
from metabolic studies in three of the 12 patients of our 
series. In patient 2, Bilheimer et a1.20 showed that cho-
lesterol and LDL syntheses, which were inappropriately 
high before portacaval shunt, were reduced afterwards 
by 62% and 48%, respectively. The fractional catabolic 
rate that was only a third of normal at the outset, as is 
typical for FH, fell further after operation. Ginsberg et 
a1.48 studied the heterozygous patient 6, who responded 
to portal diversion with major reductions in LDL as well 
as VLDL apoprotein-B synthesis, in VLDL triglyceride 
synthesis, and in the already subnormal fractional cat-
abolic rate. 
The extraordinary degree to which cholesterol ho-
meostasis was altered by portacaval shunt in the ho-
mozygous patient 4 and the heterozygous patient 6 has 
been shown by McNamara et al.49 Exogenous choles-
terol absorption was unchanged in both patients and 
bile acid synthesis was halved. Whole body cholesterol 
synthesis was decreased by 68% in patient 4 and by 41 % 
in patient 6. The total body cholesterol mass 11/2 years 
after portacaval shunt had been reduced by 59% in pa-
tient 4 and by 43% in patient 6. These data are com-
patible with the extraordinary diminution or disappear-
ance of tendinocutaneous xanthomas and with the hope 
that the lethal cardiovascular complications of FH can 
be slowed or forestalled by portacaval shunt. 
However, the degree to which cardiovascular com-
plications can be relieved or prevented by portal diver-
sion has not been established. Reversal of aortic stenosis 
was seen, but regression of atheromas in the coronary 
arteries and aorta was not regularly accomplished. Small 
and Shipley50 have examined the factors that could pre-
clude the reversal of atherosclerosis, and some of these, 
including secondary fibrosis, would not be corrected 
completely by the resorption of intravascular xantho-
mas. Farriaux et al.31 have suggested that anatomic sta-
bilization of the vascular disease may be the best that 
can be hoped for with portacaval shunt, even in patients 
whose angina pectoris is relieved. The experience with 
patient 2 has shown the value of aggressive surgical cor-
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rection of technically remedial lesions. Others have rec-
ommended the combination of portal diversion with 
corrective cardiovascular surgery.7,1l 
Of far greater importance will be the implementation 
of aggressive therapy at a young age, before the devel-
opment of irreversible cardiovascular complications. In 
patients with FH who are refractory to therapy with diet 
and medications, portacaval shunt may be the treatment 
of choice. After operation, medications and diet should 
be tried again, since further drops in post-shunt choles-
terol levels have been seen using diet and medications 
that were previously ineffective. Baker et al. 51 have re-
ported an encouraging experience with probucol in five 
patients who had had variable responses to previous 
portacaval shunts. The experience with patient 5 sug-
gested that plasmapheresis may become a procedure 
more acceptable to patients because of slower rebounds 
of plasma cholesterol levels between treatments. 
The staged combination of portacaval shunt and the 
ileal bypass procedure of Buchwald et al.52 has been 
tested in three patients with an apparently additive ef-
fect,IO,12 in spite of the fact that ileal bypass alone has 
little or no effect in homozygous FH.52 In dogs, Guzman 
et al.53 have noted an additive effect of portal diversion 
by portacaval transposition plus ileal resection. If the 
depression of bile acid synthesis, noted by Bilheimer et 
al.20 and McNamara et al.,49 after portacaval shunt for 
FH can inhibit the increased bile acid synthesis that is 
normally caused by ileal bypass in response to increased 
bile acid excretion, 52 an accelerated secondary depletion 
of the cholesterol pool might be expected. 
Portacaval shunt, with or without supplementary 
treatment, provides palliation only for patients with FH. 
The amelioration of the abnormal metabolic patterns 
of FH has derived from the countervailing and poten-
tially dangerous abnormalities caused by portacaval 
shunt. The palliation has been incomplete, since resto-
ration of normal serum cholesterol values has not been 
achieved in any patient with homozygous disease. Be-
cause of the evidence of a central hepatic role in the 
regulation of lipid metabolism, 54-57 it is possible that the 
metabolic abnormalities of FH could be rectified by the 
ultimate step ofliver transplantation. The list of inborn 
errors of metabolism already corrected by liver trans-
plantation has become a long one. 58 
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vein thrombosis or from cavernomatous transformation of the portal 
vein. 
PRESIDENT WARREN: This is a beautiful presentation by Dr. Torn 
Starzl, who is a fantastic student of human biology. This presentation 
is a major contribution to the study of lipid metabolism, as well as to 
that of the Eck fistula in man. When you look at his data, it will become 
clear that these are some of the most important findings to become 
available to us in this field. 
I think it is much too early to draw the conclusion that an Eck fistula, 
in the presence of a nonnalliver mass, is nonencephalophaly producing. 
In fact, I will predict,as r have so often with things that Sy Schwartz 
has said in the past, that Dr. Starzl is wrong again. (Laughter) 
Some of you will recall that we presented before this Association a 
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group of patients with portal vein thrombosis who had total shunts with 
complete decompression of the portal system. In this group it took about 
20 years-that is, 20 years in the human-to produce encephalopathy. 
With that time span, that is a perfectly good risk in the patients in Tom 
Starzl's series, because their inherent risk from their hyperlipidemic is 
so enormous, and lowering of the lipids is the key to the success of the 
procedure. In portal vein thrombosis, however, there is an operation in 
which you do not lose portal flow, and such patients need not become 
an Eck-fistula human preparation. 
IfI would remember simply this, that with a normal liver cell mass, 
in contrast to the baboon, as Starzl has pointed out specifically, the 
delay before encephalopathy is very, very long. Its importance, however, 
has recently been emphasized by the study of an anomaly in the Krebs-
Henseleit cycle in the ornithine transcarbamoylase deficiency in which 
very minimal elevations of ammonia ultimately lead to encephalopathy, 
although this may take 30 years or so. 
The good news is that even after 20 years our patient with profound 
encephalopathy from a total shunt with a normal liver had virtually 
complete reversal of encephalopathy with closure of the shunt, and a 
return to an essentially normal functional status. Could you tell me how 
long post-shunt your oldest patient is? 
DR. GEORGE H. A. CLOWES, JR. (Boston, Massachusetts): In the first 
part of his paper, Dr. Starzl listed a number of metabolic effects that 
are created by injury to the liver following portacaval shunt. Now, I 
would like to draw to your attention another one that's proving to be 
of great use at the present time: namely, the study of amino acid clearance 
by the liver in portacaval shunt, prior to portacaval shunt. 
Two things have come out of this. It turnS out that the total amino 
acid clearance of the liver can be measured in terms of amino acids 
cleared from plasma, and a normal clearance in response to injury or 
sepsis would be in the vicinity of 300 cc of plasma/sq m/m. In people 
who survive portacaval shunt, the average value has turned out to be 
something like 260 cc/m. And in those who died of metabolic deaths 
after surgery, it was only 180 cc. 
This is a very significant difference, with a P value of something less 
than 0.001, and I believe that it explains in part the hyperlipidemia 
problem that Dr. Starzl told us about; namely that the protein synthesis 
is very closely related to VL/DL, and all the other aspects of cholesterol 
chemistry. I would urge you to use this method of amino acid clearance 
as a means for studying your patients preoperatively, and also for finding 
out what happens to them in the post-shunt period. I believe that in 
the near future amino acid metabolism and protein synthesis will fall 
together in relation to energy production, fat metabolism, and gluco-
neogenesis. 
DR. HARRY H. LEVEEN (Charleston, South Carolina): Some years 
ago, in studying insulin-deficiency diabetes, we were able to show that 
the animals who had their insulin from the splenic vein diverted to the 
systemic circulation, rather than going through the liver, lessened their 
diabetes. 
We also noticed that the cholesterol levels in humans injected with 
insulin into the portal vein dropped quite precipitously, and we wondered 
whether this might not account for the rapid atherosclerosis that is seen 
(I) after pancreatectomy with diabetes, and (2) in diabetics taking insulin 
systemically. Diabetics who are on insulin always inject their insulin 
systemically. 
We took a series of 15 diabetics, and converted their insulin admin-
istration from systemic, in their arm, or wherever they injected it-we 
injected it intraperitoneally, and we were able to demonstrate that there 
was a good fall in circulating cholesterol values in those diabetics receiving 
their insulin intraportally. 
I wonder whether or not some of the derangements that are seen in 
the liver that are adverse might not possibly be averted by (I) diverting 
the blood flow from the spleen, rather than the entire portal system, or 
(2) injecting some insulin intraportally; even though these patients are 
not diabetic, the delivery of insulin into the portal system might alleviate 
some of their normal ammonia. 
DR. THOMAS E. STARZL (Closing discussion): I would like to thank 
the discussants, Drs. Schwartz, Warren, Clowes, and Leveen. The subjects 
that Dr. Leveen has raised are important, but they are so complex that 
it would require a good deal of time to give them adequate discussion. 
Dr. Leveen has raised the issue of whether in diabetes mellitus the proper 
drug (insulin) is being given by an improper route. This possibility is 
something that has fascinated many workers going back for at least 2 
decades. I would be remiss in not mentioning the very fine work that 
Dr. Bill Waddell did on this question between 15 and 20 years ago. 
Concerning the other discussants, I am in the unusual position, which 
I have been seeking lately, of agreeing with everybody. And to agree 
with Sy Schwartz and Dean Warren at the same time is quite a trick. 
(Laughter) 
What we are looking at here is a balancing of benefits and penalties 
for this operation. I do believe that the portacaval shunt is a very damaging 
operation which in the circumstance of familial hypercholesterolemia 
is worth doing, since the benefits exceed the penalties. 
But, we are looking at a procedure which requires, for its ultimate 
metabolic objectives, complete portal blood diversion; and that is some-
thing which in clinical practice I personally hate to do. Complete portal 
diversion puts the patient at potential jeopardy. I agree with Sy Schwartz 
about the relative safety of portal diversion in patients with normal and 
familial hypercholesterolemia or with extrahepatic block. But, in principle, 
I believe that the Warren procedure is the best kind of operation to be 
carried out for patients for whom you have the strictly mechanical 
objective of decompressing esophageal varices, because the same benefits 
can be realized, as with complete diversion but without paying a po-
tentially terrible physiologic penalty. Our longest follow-up is over 9 
years. Thank you very much. 
